A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nab-paclitaxel
Related studies linked through entity extraction aliases.
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
- Status
- RECRUITING
- Phase
- PHASE2
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2